Acumen Pharmaceuticals, Inc. ABOS
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) is a CNS/neurology/psychiatry drug developer. Its lead program, sabirnetug, is in Phase 2 for Alzheimer's disease (mild cognitive impairment or mild dementia due to AD). Its next catalyst on record is EBD® development candidates (ACU301 / ACU401): IND application submission for lead candidate (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EBD® development candidates (ACU301 / ACU401) — IND application submission for lead candidate (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| sabirnetug | Alzheimer's disease (early AD) | antibody | Phase 2 |
| ACU301 and ACU401 (EBD® development candidates) | Alzheimer's disease | antibody | Pre-clinical |
Recent results and decisions
- Oct 30, 2026missed Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's disease did not meet primary endpoint of change from baseline in cognitive and functional decline as measured by iADRS at 18 months.
Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.